Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Itovebi vs Orserdu: how two US-approved medicines for advanced breast cancer compare

Creator: Reserve Meds
Published: 2026-10-17

A side-by-side guide for families in the Gulf, built from the US FDA labels, Gulf drug registers and official sources.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Facts on this page come from the current US prescribing information for each medicine.

Itovebi vs Orserdu: the short answer

Itovebi and Orserdu are both US FDA-approved for advanced breast cancer, but for different patients and in different ways. No trial has compared them head to head. Your specialist decides which, if either, fits. Reserve Meds is a digital health company. We do not diagnose or prescribe.

Condition: advanced breast cancer.
Main difference: They are for different gene changes and different points in treatment.
Head-to-head evidence: none in either US label.
Price: Quote on request.

Itovebi and Orserdu side by side

The table summarizes each current US label. Labels are long; your specialist and hospital pharmacy work from the full text.

Feature	Itovebi	Orserdu
Generic name	inavolisib^[2]	elacestrant^[3]
Type of medicine	kinase inhibitor (it inhibits PI3K, mainly PI3K-alpha) taken by mouth, used with palbociclib and fulvestrant^[2]	estrogen receptor antagonist taken by mouth^[3]
US-approved for	With palbociclib and fulvestrant, adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer, detected by an FDA-approved test, after recurrence on or after completing adjuvant endocrine therapy.^[2]	Postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, detected by an FDA-authorized test, whose disease progressed after at least one line of endocrine therapy.^[3]
First US approval (year on the label)	2024^[2]	2023^[3]
How it is given	One 9 mg tablet by mouth once daily, with or without food, with palbociclib and fulvestrant.^[2]	One 345 mg tablet by mouth once daily with food.^[3]
Where and what to expect	Taken at home. Fasting blood sugar and HbA1c are checked and optimized before starting and at regular intervals during treatment.^[2]	Taken at home. Blood lipids are checked before starting and from time to time during treatment.^[3]
Boxed warning	No boxed warning. Warnings: high blood sugar (which can be severe), mouth sores (stomatitis), diarrhea, and harm to an unborn baby.^[2]	No boxed warning. Warnings: raised cholesterol and triglycerides, and harm to an unborn baby.^[3]

About advanced breast cancer and these two medicines

Breast cancer is a cancer that starts in breast tissue. It happens when cells in the breast change and grow out of control. If the cancer spreads to other parts of the body through the lymph system or the blood, it is called metastatic.^[1]

Itovebi and Orserdu are both for HER2-negative advanced breast cancer that is hormone receptor-positive (Itovebi label) or estrogen receptor-positive (Orserdu label), and both need a specific gene change found by a blood test: a PIK3CA mutation for Itovebi and an ESR1 mutation for Orserdu. The labels name FDA-approved or FDA-authorized tests for this.^{[2, 3]}

The main difference

They are for different gene changes and different points in treatment. Itovebi is for PIK3CA-mutated disease that came back during or after adjuvant hormone therapy, and it is taken with palbociclib and fulvestrant. Orserdu is for ESR1-mutated disease that progressed after at least one line of hormone therapy, and it is taken alone.^{[2, 3]}

The evidence behind each approval

Itovebi. INAVO120 was a randomized, double-blind, placebo-controlled trial in 325 patients. Itovebi or placebo was added to palbociclib and fulvestrant, and the major efficacy outcome was progression-free survival.^[2]

Orserdu. EMERALD was a randomized, open-label trial in 478 patients, 228 of whom had ESR1 mutations. It compared Orserdu with the investigator's choice of fulvestrant or an aromatase inhibitor, and the major efficacy outcome was progression-free survival.^[3]

No head-to-head trial. Neither US label reports a study that compared Itovebi directly with Orserdu. The trials above enrolled different patients at different stages, so their results cannot be set side by side to decide which medicine works better.

Using one after the other

The tests look for each gene change separately. Neither label reports a study of the two medicines together or one after the other. Your oncologist decides based on the test results and earlier treatment.^{[2, 3]}

Safety: what the labels warn about

Both labels list warnings that the treating team monitors. The boxed warning row in the table above is the most serious level of warning on a US label.

Itovebi: common side effects listed on the label include low neutrophils, low hemoglobin, raised fasting glucose, low platelets, mouth sores and diarrhea.^[2]
Orserdu: common side effects listed on the label include musculoskeletal pain, nausea, raised cholesterol, raised liver enzymes (AST), raised triglycerides and fatigue.^[3]

Availability in the Gulf

Itovebi: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Bahrain, Egypt
Orserdu: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Egypt

How families in the Gulf can access Itovebi or Orserdu

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks it, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[6, 7]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only and we do not choose between medicines.

Ask us about Itovebi or Orserdu

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Which is better, Itovebi or Orserdu?

There is no head-to-head trial, so no one can say from the evidence that one is better. They are approved for different patients and are given differently. Your specialist decides which fits, based on prior treatment, test results and overall health.

What is the main difference between Itovebi and Orserdu?

Are Itovebi and Orserdu available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list.

How can a family in the Gulf get Itovebi or Orserdu?

Ask the treating hospital about local supply first. If the medicine is not registered, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.

How much do these medicines cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds choose the medicine?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or choose between medicines. Your specialist and hospital make the medical decisions.

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.